A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies

[91] Rutherford JD(1999)Economic evaluation in the field of cardiology: theory and practice Prog Cardiovasc Dis 42 167-589

[92] Cole TG(1995)Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression GRowth Evaluation Statin Study (REGRESS) Circulation 91 2528-2

[93] Hay JW(1990)Medical costs of coronary artery disease in the United States Am J Cardiol 65 432-450

[94] Sterling KL(1998)Direct medical costs of coronary artery disease in the United States Am J Cardiol 81 1110-undefined

[95] Rubins HB(2003)The economic burden of stroke in the United Kingdom Pharmacoeconomics. 21 43-undefined

[96] Robins SJ(2005)Annual cost of ischemic heart disease in Brazil. Public and private perspective Arq Bras Cardiol 85 3-undefined

[97] Collins D(2009)Acute treatment costs of stroke in Brazil Neuroepidemiology. 32 142-undefined

[98] Fye CL(2008)Comparative costs between myocardial revascularization with or without extracorporeal circulation Arq Bras Cardiol 91 340-undefined

[99] Anderson JW(2013)Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients Int J Cardiol 166 431-undefined

[100] Elam MB(1998)Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial Ann Intern Med 129 581-undefined

[91] Rutherford JD(1999)Economic evaluation in the field of cardiology: theory and practice Prog Cardiovasc Dis 42 167-589

[92] Cole TG(1995)Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression GRowth Evaluation Statin Study (REGRESS) Circulation 91 2528-2

[93] Hay JW(1990)Medical costs of coronary artery disease in the United States Am J Cardiol 65 432-450

[94] Sterling KL(1998)Direct medical costs of coronary artery disease in the United States Am J Cardiol 81 1110-undefined

[95] Rubins HB(2003)The economic burden of stroke in the United Kingdom Pharmacoeconomics. 21 43-undefined

[96] Robins SJ(2005)Annual cost of ischemic heart disease in Brazil. Public and private perspective Arq Bras Cardiol 85 3-undefined

[97] Collins D(2009)Acute treatment costs of stroke in Brazil Neuroepidemiology. 32 142-undefined

[98] Fye CL(2008)Comparative costs between myocardial revascularization with or without extracorporeal circulation Arq Bras Cardiol 91 340-undefined

[99] Anderson JW(2013)Impact of statin dose on major cardiovascular events: a mixed treatment comparison meta-analysis involving more than 175,000 patients Int J Cardiol 166 431-undefined

[100] Elam MB(1998)Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial Ann Intern Med 129 581-undefined